{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:55:09Z","timestamp":1771484109719,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004590","name":"Helse Midt-Norge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Blood biomarkers for early detection of lung cancer (LC) are in demand. There are few studies of the full microRNome in serum of asymptomatic subjects that later develop LC. Here we searched for novel microRNA biomarkers in blood from non-cancer, ever-smokers populations up to eight years before diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Serum samples from 98,737 subjects from two prospective population studies, HUNT2 and HUNT3, were considered initially. Inclusion criteria for cases were: ever-smokers; no known cancer at study entrance; 0\u20138\u00a0years from blood sampling to LC diagnosis. Each future LC case had one control matched to sex, age at study entrance, pack-years, smoking cessation time, and similar HUNT Lung Cancer Model risk score. A total of 240 and 72 serum samples were included in the discovery (HUNT2) and validation (HUNT3) datasets, respectively, and analysed by next-generation sequencing. The validated serum microRNAs were also tested in two pre-diagnostic plasma datasets from the prospective population studies NOWAC (n\u2009=\u2009266) and NSHDS (n\u2009=\u2009258). A new model adding clinical variables was also developed and validated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifteen unique microRNAs were discovered and validated in the pre-diagnostic serum datasets when all cases were contrasted against all controls, all with AUC\u2009&gt;\u20090.60. In combination as a 15-microRNAs signature, the AUC reached 0.708 (discovery) and 0.703 (validation). A non-small cell lung cancer signature of six microRNAs showed AUC 0.777 (discovery) and 0.806 (validation). Combined with clinical variables of the HUNT Lung Cancer Model (age, gender, pack-years, daily cough parts of the year, hours of indoor smoke exposure, quit time in years, number of cigarettes daily, body mass index (BMI)) the AUC reached 0.790 (discovery) and 0.833 (validation). These results could not be validated in the plasma samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There were a few significantly differential expressed microRNAs in serum up to eight years before diagnosis. These promising microRNAs alone, in concert, or combined with clinical variables have the potential to serve as early diagnostic LC biomarkers. Plasma is not suitable for this analysis. Further validation in larger prospective serum datasets is needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05882-4","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T12:01:48Z","timestamp":1721476908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Promising microRNAs in pre-diagnostic serum associated with lung cancer up to eight years before diagnosis: a HUNT study"],"prefix":"10.1007","volume":"150","author":[{"given":"Ioannis","family":"Fotopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olav Toai Duc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese Haugdahl","family":"N\u00f8st","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Markaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Lagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Mjelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torkjel Manning","family":"Sandanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"S\u00e6trom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Tsamardinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluf Dimitri","family":"R\u00f8e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"5882_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"DR Aberle","year":"2011","unstructured":"Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM et al (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395\u2013409. https:\/\/doi.org\/10.1056\/NEJMoa1102873","journal-title":"N Engl J Med"},{"key":"5882_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (methodological). 57:289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x","journal-title":"J R Stat Soc Ser B (methodological)."},{"key":"5882_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/emmm.201100154","volume":"3","author":"F Bianchi","year":"2011","unstructured":"Bianchi F, Nicassio F, Marzi M, Belloni E, Dall\u2019olio V, Bernard L et al (2011) A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3:495\u2013503. https:\/\/doi.org\/10.1002\/emmm.201100154","journal-title":"EMBO Mol Med"},{"key":"5882_CR4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/jcm8101661","volume":"8","author":"M Bottani","year":"2019","unstructured":"Bottani M, Banfi G, Lombardi G (2019) Circulating miRNAs as diagnostic and prognostic biomarkers in common solid tumors: focus on lung, breast, prostate cancers, and osteosarcoma. J Clin Med 8:1661","journal-title":"J Clin Med"},{"key":"5882_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020276","author":"CE Condrat","year":"2020","unstructured":"Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D et al (2020) miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. https:\/\/doi.org\/10.3390\/cells9020276","journal-title":"Cells"},{"key":"5882_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ de Koning","year":"2020","unstructured":"de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA et al (2020) Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 382:503\u2013513. https:\/\/doi.org\/10.1056\/NEJMoa1911793","journal-title":"N Engl J Med"},{"key":"5882_CR7","doi-asserted-by":"publisher","first-page":"37250","DOI":"10.18632\/oncotarget.9363","volume":"7","author":"AR Halvorsen","year":"2016","unstructured":"Halvorsen AR, Bjaanaes M, LeBlanc M, Holm AM, Bolstad N, Rubio L et al (2016) A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget 7:37250\u201337259. https:\/\/doi.org\/10.18632\/oncotarget.9363","journal-title":"Oncotarget"},{"key":"5882_CR8","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.21037\/jtd.2018.05.32","volume":"10","author":"Y Han","year":"2018","unstructured":"Han Y, Li H (2018) miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC). J Thorac Dis 10:3119\u20133131. https:\/\/doi.org\/10.21037\/jtd.2018.05.32","journal-title":"J Thorac Dis"},{"key":"5882_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2006","unstructured":"Johnson WE, Li C, Rabinovic A (2006) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8:118\u2013127. https:\/\/doi.org\/10.1093\/biostatistics\/kxj037","journal-title":"Biostatistics"},{"key":"5882_CR10","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","volume":"55","author":"T Kim","year":"2023","unstructured":"Kim T, Croce CM (2023) MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp Mol Med 55:1314\u20131321. https:\/\/doi.org\/10.1038\/s12276-023-01050-9","journal-title":"Exp Mol Med"},{"key":"5882_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fgene.2013.00094","volume":"4","author":"MB Kirschner","year":"2013","unstructured":"Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G (2013) The impact of hemolysis on cell-free microRNA biomarkers. Front Genet 4:94. https:\/\/doi.org\/10.3389\/fgene.2013.00094","journal-title":"Front Genet"},{"key":"5882_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/ije\/dys095","volume":"42","author":"S Krokstad","year":"2013","unstructured":"Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR et al (2013) Cohort profile: the HUNT Study, Norway. Int J Epidemiol 42:968\u2013977. https:\/\/doi.org\/10.1093\/ije\/dys095","journal-title":"Int J Epidemiol"},{"key":"5882_CR13","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law CW, Chen Y, Shi W, Smyth GK (2014) voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15:R29. https:\/\/doi.org\/10.1186\/gb-2014-15-2-r29","journal-title":"Genome Biol"},{"key":"5882_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.12688\/f1000research.9005.3","volume":"5","author":"CAM Law","year":"2018","unstructured":"Law CAM, Su S, Dong X, Tian L, Smyth GK, Ritchie ME (2018) RNA-seq analysis is easy as 1\u20132\u20133 with limma Glimma and edgeR [version 3; peer review: 3 approved]. F1000Research 5:1408","journal-title":"F1000Research"},{"key":"5882_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv412","volume":"43","author":"R Liu","year":"2015","unstructured":"Liu R, Holik AZ, Su S, Jansz N, Chen K, Leong HS et al (2015) Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. Nucleic Acids Res 43:e97. https:\/\/doi.org\/10.1093\/nar\/gkv412","journal-title":"Nucleic Acids Res"},{"key":"5882_CR16","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163\u2013170","journal-title":"Cancer Chemother Rep"},{"key":"5882_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ebiom.2018.03.027","volume":"31","author":"M Markaki","year":"2018","unstructured":"Markaki M, Tsamardinos I, Langhammer A, Lagani V, Hveem K, R\u00f8e OD (2018) A validated clinical risk prediction model for lung cancer in smokers of all ages and exposure types: a HUNT study. EBioMedicine 31:36\u201346. https:\/\/doi.org\/10.1016\/j.ebiom.2018.03.027","journal-title":"EBioMedicine"},{"key":"5882_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227648","volume":"15","author":"PR Matias-Garcia","year":"2020","unstructured":"Matias-Garcia PR, Wilson R, Mussack V, Reischl E, Waldenberger M, Gieger C et al (2020) Impact of long-term storage and freeze-thawing on eight circulating microRNAs in plasma samples. PLoS ONE 15:e0227648. https:\/\/doi.org\/10.1371\/journal.pone.0227648","journal-title":"PLoS ONE"},{"key":"5882_CR19","doi-asserted-by":"publisher","first-page":"90077","DOI":"10.18632\/oncotarget.21412","volume":"8","author":"R Mjelle","year":"2017","unstructured":"Mjelle R, Sell\u00e6g K, S\u00e6trom P, Thommesen L, Sjursen W, Hofsli E (2017) Identification of metastasis-associated microRNAs in serum from rectal cancer patients. Oncotarget 8:90077\u201390089. https:\/\/doi.org\/10.18632\/oncotarget.21412","journal-title":"Oncotarget"},{"key":"5882_CR20","doi-asserted-by":"publisher","first-page":"djv063","DOI":"10.1093\/jnci\/djv063","volume":"107","author":"F Montani","year":"2015","unstructured":"Montani F, Marzi MJ, Dezi F, Dama E, Carletti RM, Bonizzi G et al (2015) miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst 107:djv063. https:\/\/doi.org\/10.1093\/jnci\/djv063","journal-title":"J Natl Cancer Inst"},{"key":"5882_CR21","unstructured":"National Cancer Institute (2022) Cancer Stat Facts: lung and bronchus cancer. [Internet]. [cited February 19, 2022]. https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html"},{"key":"5882_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/1878-0261.13336","volume":"17","author":"TH N\u00f8st","year":"2023","unstructured":"N\u00f8st TH, Skogholt AH, Urbarova I, Mjelle R, Paulsen EE, D\u00f8nnem T et al (2023) Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer. Mol Oncol 17:312\u2013327. https:\/\/doi.org\/10.1002\/1878-0261.13336","journal-title":"Mol Oncol"},{"key":"5882_CR23","doi-asserted-by":"publisher","first-page":"16699","DOI":"10.1038\/s41598-018-35139-3","volume":"8","author":"J Pan","year":"2018","unstructured":"Pan J, Zhou C, Zhao X, He J, Tian H, Shen W et al (2018) A two-miRNA signature (miR-33a-5p and miR-128-3p) in whole blood as potential biomarker for early diagnosis of lung cancer. Sci Rep 8:16699. https:\/\/doi.org\/10.1038\/s41598-018-35139-3","journal-title":"Sci Rep"},{"key":"5882_CR24","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce CM (2016) The role of microRNAs in human cancer. Signal Transduct Target Ther 1:15004. https:\/\/doi.org\/10.1038\/sigtrans.2015.4","journal-title":"Signal Transduct Target Ther"},{"key":"5882_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3892\/ol.2016.5452","volume":"13","author":"S Pizzamiglio","year":"2017","unstructured":"Pizzamiglio S, Zanutto S, Ciniselli CM, Belfiore A, Bottelli S, Gariboldi M et al (2017) A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncol Lett 13:315\u2013320. https:\/\/doi.org\/10.3892\/ol.2016.5452","journal-title":"Oncol Lett"},{"key":"5882_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https:\/\/doi.org\/10.1093\/nar\/gkv007","journal-title":"Nucleic Acids Res"},{"key":"5882_CR27","doi-asserted-by":"publisher","first-page":"17650","DOI":"10.1038\/s41598-018-35974-4","volume":"8","author":"TB Rounge","year":"2018","unstructured":"Rounge TB, Umu SU, Keller A, Meese E, Ursin G, Tretli S et al (2018) Circulating small non-coding RNAs associated with age, sex, smoking, body mass and physical activity. Sci Rep 8:17650. https:\/\/doi.org\/10.1038\/s41598-018-35974-4","journal-title":"Sci Rep"},{"key":"5882_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jtho.2018.11.023","volume":"14","author":"LM Seijo","year":"2019","unstructured":"Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G et al (2019) Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol 14:343\u2013357. https:\/\/doi.org\/10.1016\/j.jtho.2018.11.023","journal-title":"J Thorac Oncol"},{"key":"5882_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jtho.2015.10.014","volume":"11","author":"M Silva","year":"2016","unstructured":"Silva M, Galeone C, Sverzellati N, Marchian\u00f2 A, Calareso G, Sestini S et al (2016) Screening with low-dose computed tomography does not improve survival of small cell lung cancer. J Thorac Oncol 11:187\u2013193. https:\/\/doi.org\/10.1016\/j.jtho.2015.10.014","journal-title":"J Thorac Oncol"},{"key":"5882_CR30","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/jco.2013.50.4357","volume":"32","author":"G Sozzi","year":"2014","unstructured":"Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F et al (2014) Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 32:768\u2013773. https:\/\/doi.org\/10.1200\/jco.2013.50.4357","journal-title":"J Clin Oncol"},{"key":"5882_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20407\/fmj.2.1_1","volume":"2","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamada H, Nagura A, Ohashi K, Ishikawa H, Yamazaki M et al (2016) Association of cigarette smoking with serum microRNA expression among middle-aged Japanese adults. Fujita Med J 2:1\u20135. https:\/\/doi.org\/10.20407\/fmj.2.1_1","journal-title":"Fujita Med J"},{"key":"5882_CR32","unstructured":"Team RC (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. https:\/\/www.r-project.org."},{"key":"5882_CR33","unstructured":"Technology NUoSa (2020) Participation numbers. Norwegian University of Science and Technology. https:\/\/www.ntnu.edu\/hunt\/participation. Accessed 31 Oct 2020"},{"key":"5882_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/1878-0261.12620","volume":"14","author":"SU Umu","year":"2020","unstructured":"Umu SU, Langseth H, Keller A, Meese E, Helland \u00c5, Lyle R et al (2020) A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis. Mol Oncol 14:235\u2013247. https:\/\/doi.org\/10.1002\/1878-0261.12620","journal-title":"Mol Oncol"},{"key":"5882_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2024.e00376","volume":"39","author":"I Wakabayashi","year":"2024","unstructured":"Wakabayashi I, Marumo M, Ekawa K, Daimon T (2024) Differences in serum and plasma levels of microRNAs and their time-course changes after blood collection. Pract Lab Med 39:e00376. https:\/\/doi.org\/10.1016\/j.plabm.2024.e00376","journal-title":"Pract Lab Med"},{"key":"5882_CR36","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.ebiom.2015.07.034","volume":"2","author":"C Wang","year":"2015","unstructured":"Wang C, Ding M, Xia M, Chen S, Van Le A, Soto-Gil R et al (2015) A five-miRNA panel identified from a multicentric case-control study serves as a novel diagnostic tool for ethnically diverse non-small-cell lung cancer patients. EBioMedicine 2:1377\u20131385. https:\/\/doi.org\/10.1016\/j.ebiom.2015.07.034","journal-title":"EBioMedicine"},{"key":"5882_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/2211536605666161208154633","volume":"6","author":"M Williams","year":"2017","unstructured":"Williams M, Cheng YY, Blenkiron C, Reid G (2017) Exploring mechanisms of microRNA downregulation in cancer. Microrna 6:2\u201316. https:\/\/doi.org\/10.2174\/2211536605666161208154633","journal-title":"Microrna"},{"key":"5882_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125026","volume":"10","author":"MB Wozniak","year":"2015","unstructured":"Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze D, Brennan P (2015) Circulating microRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer. PLoS ONE 10:e0125026. https:\/\/doi.org\/10.1371\/journal.pone.0125026","journal-title":"PLoS ONE"},{"key":"5882_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071611","author":"KL Wu","year":"2019","unstructured":"Wu KL, Tsai YM, Lien CT, Kuo PL, Hung AJ (2019) The roles of MicroRNA in lung cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20071611","journal-title":"Int J Mol Sci"},{"key":"5882_CR40","doi-asserted-by":"publisher","first-page":"25036","DOI":"10.1073\/pnas.2006212117","volume":"117","author":"L Ying","year":"2020","unstructured":"Ying L, Du L, Zou R, Shi L, Zhang N, Jin J et al (2020) Development of a serum miRNA panel for detection of early stage non-small cell lung cancer. Proc Natl Acad Sci USA 117:25036\u201325042. https:\/\/doi.org\/10.1073\/pnas.2006212117","journal-title":"Proc Natl Acad Sci USA"},{"key":"5882_CR41","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/cac2.12346","volume":"42","author":"H Yu","year":"2022","unstructured":"Yu H, Raut JR, Bhardwaj M, Zhang Y, Sandner E, Sch\u00f6ttker B et al (2022) A serum microRNA signature for enhanced selection of people for lung cancer screening. Cancer Commun (lond) 42:1222\u20131225. https:\/\/doi.org\/10.1002\/cac2.12346","journal-title":"Cancer Commun (lond)"},{"key":"5882_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.trsl.2020.11.012","volume":"230","author":"S Zhong","year":"2021","unstructured":"Zhong S, Golpon H, Zardo P, Borlak J (2021) miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res 230:164\u2013196. https:\/\/doi.org\/10.1016\/j.trsl.2020.11.012","journal-title":"Transl Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05882-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05882-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05882-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T17:10:09Z","timestamp":1723050609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05882-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["5882"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05882-4","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no competing interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The respective Regional Committees for Medical and Health Research Ethics in Norway and Sweden approved each individual study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Participants included in the HUNT2, HUNT3, NOWAK and NSHDS cohorts all gave their written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"355"}}